Open AccessNovel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells
Author(s) -
Samuel V. Mussi,
Rupa R. Sawant,
Federico Perche,
Mônica Cristina Oliveira,
Ricardo Bentes Azevedo,
Lucas Antônio Miranda Ferreira,
Vladimir P. Torchilin
Publication year - 2014
Publication title -
pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.815
H-Index - 206
eISSN - 1573-904X
pISSN - 0724-8741
DOI - 10.1007/s11095-013-1290-2
Subject(s) - doxorubicin , cytotoxicity , pharmacology , chemistry , efflux , p glycoprotein , mcf 7 , zeta potential , drug carrier , penetration (warfare) , in vitro , nanocarriers , drug , multiple drug resistance , cancer cell , biochemistry , materials science , medicine , nanotechnology , chemotherapy , nanoparticle , cancer , operations research , human breast , engineering , antibiotics
To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom